Related references
Note: Only part of the references are listed.The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Daniel Sanghoon Shin et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
George K. Philips et al.
INTERNATIONAL IMMUNOLOGY (2015)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
A. Q. Butt et al.
ONCOGENE (2014)
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
L. B. Jilaveanu et al.
JOURNAL OF CANCER (2014)
OPINION Challenges in circulating tumour cell research
Catherine Alix-Panabieres et al.
NATURE REVIEWS CANCER (2014)
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
Francois-Clement Bidard et al.
CANCER AND METASTASIS REVIEWS (2013)
Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer Patients
Yibin Kang et al.
CANCER CELL (2013)
Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?
Klaus Pantel et al.
CANCER RESEARCH (2013)
Circulating Tumor Cells: Liquid Biopsy of Cancer
Catherine Alix-Panabieres et al.
CLINICAL CHEMISTRY (2013)
Circulating Tumor Cells and Circulating Tumor DNA
Catherine Alix-Panabieres et al.
ANNUAL REVIEW OF MEDICINE, VOL 63 (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Biospecimen Reporting for Improved Study Quality (BRISQ)
Helen M. Moore et al.
JOURNAL OF PROTEOME RESEARCH (2011)
HER2-Positive Circulating Tumor Cells in Breast Cancer
Michail Ignatiadis et al.
PLOS ONE (2011)
Controversies in clinical cancer dormancy
Jonathan W. Uhra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2010)
Circulating tumour cells in cancer patients: challenges and perspectives
Klaus Pantel et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Does tumour dormancy offer a therapeutic target?
Paul E. Goss et al.
NATURE REVIEWS CANCER (2010)
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Klaus Pantel et al.
NATURE REVIEWS CANCER (2008)
Metastasis: recent discoveries and novel treatment strategies
Suzanne A. Eccles et al.
LANCET (2007)
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer:: A validation study of the CellSearch system
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2007)
A pooled analysis of bone marrow micrometastasis in breast cancer
S Braun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Dissemination and growth of cancer cells in metastatic sites
AF Chambers et al.
NATURE REVIEWS CANCER (2002)
Share Paper
